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Background. The epidemiology of acute hepatitis C has changed during the past decade in Western countries.
Acute HCV infection has a high rate of chronicity, but it is unclear when patients with acute infection should be
treated.
Methods. To evaluate current sources of hepatitis C virus (HCV) transmission in Italy and to assess the rate
of and factors associated with chronic infection, we enrolled 214 consecutive patients with newly acquired hepatitis
C during 1999–2004. The patients were from 12 health care centers throughout the country, and they were followed
up for a mean ( SD) period of months. Biochemical liver tests were performed, and HCV RNA levels14 15.8
were monitored.
Results. A total of 146 patients (68%) had symptomatic disease. The most common risk factors for acquiring
hepatitis C that were reported were intravenous drug use and medical procedures. The proportion of subjects
with spontaneous resolution of infection was 36%. The average timespan from disease onset to HCV RNA clearance
was 71 days (range, 27–173 days). In fact, 58 (80%) of 73 patients with self-limiting hepatitis experienced HCV
RNA clearance within 3 months of disease onset. Multiple logistic regression analyses showed that none of the
variables considered (including asymptomatic disease) were associated with increased risk of developing chronic
hepatitis C.
Conclusions. These findings underscore the importance of medical procedures as risk factors in the current
spread of HCV infection in Italy. Because nearly all patients with acute, self-limiting hepatitis C—both symptomatic
and asymptomatic—have spontaneous viral clearance within 3 months of disease onset, it seems reasonable to
start treatment after this time period ends to avoid costly and useless treatment.
The epidemiology of acute hepatitis C has changed dur-
ing the past decades, and the incidence of new infection
has decreased in most developed countries. The intro-
duction of more accurate and sensitive screening tests
has led to the control of hepatitis C associated with
blood transfusion and administration of blood deriv-
Received 24 April 2006; accepted 16 June 2006; electronically published 27
September 2006.
Reprints or correspondence: Dr. Teresa Santantonio, Clinic of Infectious
Diseases, University of Bari, Policlinico, Piazza Giulio Cesare 11, Bari, Italy 70124
(t.santantonio@clininf.uniba.it).
Clinical Infectious Diseases 2006; 43:1154–9
 2006 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2006/4309-0005$15.00
atives [1]. Moreover, the general improvement in hy-
giene and sanitary conditions and the campaign for
prevention of HIV infection have all contributed to the
decrease in the incidence of new infections.
Nevertheless, new cases of hepatitis C still occur each
year. In the United States, 40,000 cases of acute hepatitis
C virus (HCV) infection per year are currently reported
[2]. In Italy, according to data from the national sur-
veillance system specifically for acute viral hepatitis (Sis-
tema Epidemiologico Integrato dell’Epatite Virale
Acuta), the incidence of acute HCV infection has de-
creased from nearly 3 cases per 100,000 population in
1989 to 1 case per 100,000 in 2001 [3]. However, this
figure is probably underestimated, because it mainly
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Table 1. Demographic, clinical and serological characteristics of 214
patients with acute hepatitis C.
Characteristic Patients
Age
Mean years  SD (range) 37.5 (17–83)
30 years old 100 (46.7)
31–45 years old 52 (24.3)
145 years old 62 (29.0)
Sex, no. male/no. female 140/74
Region of residence
Northern Italy 83 (38.8)
Central Italy 40 (18.7)




Bilirubin level, mean mg/dL  SD (range) 4.63  5.6
(0.42–36.76)









Anti-HCV seroconversion 135 (63.1)
Presence of HBsAg
Detected 2 (0.9)








Not detected 164 (76.6)
Undetermined 17 (8.0)
Follow-up, mean months  SD (range) 14  15.8 (6–74)
NOTE. Data are no. (%) of patients, unless otherwise indicated. ALT, alanine ami-
notransferase; HBc, hepatitis B core antigen; HBsAg, hepatitis B surface antigen; HCV,
hepatitis C virus; NA, not available.
a Normal value, 40 IU/mL.
refers to symptomatic patients; it is well known that the ma-
jority of acute HCV cases are asymptomatic and, therefore,
elude clinical observation. In agreement with this hypothesis,
a higher incidence of 2.4 cases per 100,000 population was
found in a study conducted with periodic blood donors [4];
moreover, a figure as high as 14 cases per 100,000 population
has been reported in a random sample of the general population
[5]. Taking into account these considerations, it is accurate to
say that several thousand new cases occur each year in Italy.
These findings underscore the importance of determining
the current patterns of HCV transmission to obtain a complete
and updated picture of the potential sources of infection. More-
over, because acute hepatitis C progresses to chronic infection
in 43%–86% of patients [6] and because there is clear evidence
that antiviral therapy during the acute phase of HCV infection
significantly reduces evolution to chronic illness [7, 8], the
identification of patients with newly acquired hepatitis C is
useful to the prevention of chronic hepatitis.
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Table 2. Potential non–mutually exclusive risk factors for hep-









Blood transfusion 7 (3.3)
Endoscopy 16 (7.5)
Dialysis 3 (1.4)
Dental treatment 13 (6.1)
Other invasive procedures 5 (2.3)
Needlestick injury 14 (6.5)
Tattoo and/or body piercing 8 (3.8)
Sexual contact 67 (31.3)
Household contact 9 (6.1)
Unknown 28 (13.1)
Figure 1. Risk factors for acquiring hepatitis C virus infection (when
11 risk factor was reported, a hierarchy was employed, and only the risk
factor associated with the most efficient mode of HCV transmission was
recorded).
The aims of this study were first, to evaluate the current
sources of HCV transmission in a large Italian cohort of acute
hepatitis C patients; second, to assess the factors associated with
chronicity and the rate of chronic infection; and finally, to
determine the time lag between disease onset and spontaneous
resolution.
PATIENTS AND METHODS
Patients. A total of 214 patients with acute hepatitis C treated
from 1999 to 2004 in 12 Italian health care centers throughout
the country were enrolled in the study. Each patient provided
written, informed consent before entering the study. Diagnosis
of acute hepatitis C was based on the presence of HCV RNA
in serum samples, plus either HCV antibody seroconversion
within a 6-month period or alanine aminotransferase levels that
were 120 times the upper limit of normal in previously healthy
subjects, without any other cause of acute liver damage. These
strict criteria were adopted to exclude patients with exacer-
bation of chronic hepatitis C. Onset of acute hepatitis was
established at the time of the first detection of increased serum
alanine aminotransferase levels.
We collected information regarding demographic and clinical
characteristics and potential risk factors for each patient. The
potential risk factors considered were intravenous drug use,
history of medical procedures (e.g., hospitalization, surgery,
endoscopy, dialysis, blood transfusion, dental treatment, or
other invasive procedures), needlestick injury, sexual contact,
tattoos and/or body piercing, and household contact. When no
risk factor was recorded within the 6 months prior to onset of
acute hepatitis C, the source of infection was considered to be
unknown.
All patients were followed up, and periodic biochemical and
virological tests were performed weekly during the first month
after onset of hepatitis, once a month for an additional 5
months, and once every 3 months thereafter. Patients with
spontaneous virological and biochemical resolution within 6
months of onset that lasted for at least another 6 months of
follow-up (range, 6–74 months) were considered to have self-
limiting hepatitis, whereas patients who remained viremic 6
months after onset of infection with persistently high or fluc-
tuating alanine aminotransferase levels were considered to have
chronic hepatitis, and they were offered antiviral treatment. In
Italy, IFN treatment of acute hepatitis C has been funded by
the national health service since 2005.
Virological assays. Serological markers for hepatitis A vi-
rus, HCV, hepatitis B virus, and HIV infections were tested for
with commercially available kits (Sorin Biomedica and Ortho
Diagnostic Systems). Quantitative detection of HCV RNA was
performed using a PCR assay with a sensitivity limit of 600 IU/
mL (Amplicor HCV-Monitor; Roche Diagnostic Systems) or
using a branched-DNA assay with a sensitivity limit of 615 IU/
mL (HCV RNA 3.0 Assay; Bayer). Samples that had a sensitivity
below the limit that could be detected by quantitative assays
were tested using a qualitative PCR assay with a sensitivity limit
of 50 IU/mL (Amplicor HCV; Roche Diagnostic Systems). HCV
genotyping was performed using a line probe reverse hybrid-
ization assay (INNO-LIPA HCV; Innogenetics).
Statistical analysis. Crude ORs for the association of the
likelihood of chronicity with the risk factors considered were
evaluated by univariate analysis. To identify independent pre-
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Figure 2. Cumulative frequency over time of 73 patients with spon-
taneous resolution of acute hepatitis C.










1a 22 8 (36) 14 (74)
1b 63 21 (33) 42 (77)
2a/2c 42 11 (26) 31 (74)
3 32 13 (41) 19 (59)
4 4 0 (0) 4 (100)
dictors of the likelihood of chronicity, adjusted ORs were cal-
culated by multiple logistic regression analysis.
RESULTS
During 1999–2004, a total of 214 consecutive patients with
acute hepatitis C were recruited into the study. Table 1 shows
demographic, clinical, and serological features of the study pop-
ulation. In all, 83 patients (38.8%) resided in northern Italy,
40 (18.7%) resided in central Italy, and 91 (42.5%) lived in the
south or on the islands. The mean age was 37.5 years, and the
majority of patients (65.4%) were male. Symptomatic disease
was observed in 148 (68%) of 214 patients; 121 (57%) had
jaundice, and 27 (12%) had a bilirubin level 110 mg/dL (1
patient had a maximum level of 36.76 mg/dL). Alanine ami-
notransferase levels were 120 times the upper limit of normal
in 156 patients (73%) and were 150 times the upper limit of
normal in 39 (18%; the peak level of 1 patient was 110 times
the upper limit of normal). The most common genotype de-
tected was 1b (detected in 66 patients [30.8%]). The diagnosis
of hepatitis C was made on the basis of seroconversion in 135
(63.1%) of 214 patients. In patients in whom no anti-HCV
antibodies were detected 6 months before the onset of acute
hepatitis C, testing for anti-HCV antibodies was performed
because of the presence of risk factors (such as drug addiction
or accidental exposure) or as part of laboratory procedures for
the diagnosis of other diseases. Two patients had detectable
hepatitis B surface antigen, and 6 had HIV infection. No patient
experienced fulminant disease.
Potential non–mutually exclusive risk factors experienced
during the 6 months before onset of acute HCV infection were
reported by 186 patients (87%). The most frequent risk factors
were intravenous drug use, medical procedures, and sexual con-
tact (including 12 partners in the previous 6 months), sexual
promiscuity, sex with a person with HCV infection, and men
who have sex with men (table 2). Medical procedures that were
risk factors included hospitalization, surgical intervention, en-
doscopy, blood transfusion, dialysis, dental treatment, and
other invasive diagnostic or therapeutic procedures. Among
patients who underwent surgery, abdominal, cardiovascular,
orthopedic, and ophthalmological interventions were the most
commonly reported (data not shown). Sixteen patients under-
went endoscopy (9 gastroscopies, 4 colonoscopies, 3 bron-
choscopies, and 1 arthroscopy); biopsies were performed for
10 patients. When 11 risk factor was reported, a hierarchy was
employed, and only the risk factor associated with the most
efficient mode of HCV transmission was recorded. Overall,
among 214 patients with acute hepatitis C, 69 (32%) reported
undergoing at least 1 medical procedure, and 64 (30%) were
intravenous drug users (figure 1).
Stratifying patients according to geographic area of residence,
we noted that medical procedures performed in southern Italy
and intravenous drug use by patients in the central and north-
ern regions were the most frequent risk factors observed (data
not shown). No risk factor was reported or identified in 13%
of patients.
In 203 patients who were available for the 6-month follow-
up, the outcome of acute hepatitis C was evaluated. A total of
73 patients (36%) showed spontaneous resolution of illness,
and 130 (64%) became chronic HCV carriers. The percentage
of subjects with self-limiting acute hepatitis C was 41% for
symptomatic patients but 26% for asymptomatic patients
( ). The average time from disease onset to spontaneousP ! .04
resolution was 71 days (range, 27–173 days). Interestingly, 80%
of the 73 patients with self-limiting hepatitis had HCV RNA
clearance within 3 months of disease onset, and 90% had clear-
ance within 4 months (figure 2). HCV RNA clearance occurred
earlier in the 18 patients with asymptomatic self-limiting acute
hepatitis than it did in the 55 patients with symptomatic self-
limiting infection (figure 2). The outcomes of acute hepatitis
C according to genotype are shown in table 3. Patients with
genotype 3 infection experienced the highest rate of sponta-
neous resolution. After exclusion of patients without docu-
mented anti-HCV seroconversion, the percentage of subjects
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Female 38.3 31.5 1 1
Male 61.7 68.5 1.3 (0.7–2.5) 1.5 (0.7–3.1)
Age
30 years 45.2 46.1 1 1
130 years 54.8 53.9 1.0 (0.5–1.7) 0.9 (0.4–2.0)
Asymptomatic disease 24.6 39.2 2.0 (1.0–3.8) 1.8 (0.8–3.8)
HCV genotype
Non-1 67.2 65.6 1 1
1 32.8 34.4 1.1 (0.6–2.0) 1.1 (0.5–2.2)
Anti-HBc detection 10.6 21.0 2.2 (0.9–5.6) 2.5 (0.8–7.4)
Route of transmission
Intravenous drug use 42.9 31.0 0.6 (0.3–1.2) 0.5 (0.2–1.0)
Other 57.1 69.0 1 1
NOTE. Crude and adjusted ORs were adjusted by multivariate analysis for all the variables
listed in the table, for the association of the likelihood of progression to chronic disease with
potential risk factors. HBc, hepatitis B core antigen; HCV, hepatitis C virus.
who experienced resolution of infection did not change. The
2 patients in whom hepatitis B surface antigen was detected
experienced resolution of acute hepatitis C and remained hep-
atitis B virus chronic carriers. Moreover, 3 of the 6 HIV-infected
patients with HCV superinfection experienced resolution of
HCV disease. Multiple logistic regression showed that none of
the variables considered (including asymptomatic disease) were
associated with the likelihood of chronicity (table 4).
DISCUSSION
In this study, a large cohort of 214 patients with acute hepatitis
C was recruited over 5 years (1999–2004) to evaluate the current
modes of HCV transmission and the outcome of sporadic or
community-acquired acute hepatitis C. Because data were ob-
tained from several hospitals in different parts of the country
using homogeneous diagnostic procedures, the epidemiological
picture provided herein can be considered to be representative
of the population of Italy.
The present study shows that intravenous drug use and in-
vasive medical procedures are the main modes of HCV trans-
mission in Italy. These findings are in agreement with the cor-
responding figures from Sistema Epidemiologico Integrato
dell’Epatite Virale Acuta, which identified intravenous drug use
(OR, 35.5; 95% CI, 23.1–54.4) and surgical intervention (OR,
4.6; 95% CI, 3.3–6.5) as the strongest independent predictors of
acute hepatitis C in Italy during 1994–1996 [9]. The importance
of medical procedures in the spread of HCV in the absence of
an effective vaccine emphasizes the need for the implementation
of generic preventive measures aimed at controlling this source
of exposure. Naturally, this is possible only if people are aware
of the importance of medical procedures as a mode of trans-
mission and then enact a more-precise surveillance program to
identify the exact medical practices leading to infection. Medical
procedures have also been reported to play a role in HCV trans-
mission in other studies, with a reported range of incidence of
transmission of 16%–69% [7, 10–12].
In our study, the rate of acute hepatitis C that became chronic
hepatitis C was 64%, a figure not far from the 67% [13] or the
71% [14] observed in 2 previous Italian studies of smaller co-
horts. Some studies have identified symptomatic disease as a
predictor of spontaneous viral clearance, presumably reflecting
a more effective host immune response that is capable of erad-
icating the virus by killing infected hepatocytes and is respon-
sible for clinical manifestations [15]. However, in 1 study that
revealed in univariate analysis that jaundice was a prognostic
factor of self-limiting hepatitis ( ), the authors failed toP ! .04
adjust for the influence of confounders by multiple logistic
regression analysis [13]. In another study, in which all asymp-
tomatic patients developed chronic hepatitis C, results may have
been biased by the small sample size (only 9 asymptomatic
patients were enrolled) [10]. Even in the present study, which
includes a large cohort of patients with acute HCV infection,
spontaneous HCV RNA clearance was more likely to be ob-
served in symptomatic patients than in asymptomatic patients
in univariate analysis ( ). However, after adjustment forP ! .04
the disturbing influence of confounders by multiple logistic
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regression analysis, asymptomatic disease was no longer asso-
ciated with the likelihood of chronicity (OR, 1.8; 95% CI, 0.8–
3.8). Similar results were obtained in a recent prospective study
of 34 consecutive patients with acute HCV infection in Italy
[14].
It has been suggested that host-related factors—in particular,
cell-mediated immunity—play a crucial role in the spontaneous
clearance of the virus. There is clear evidence that early, vig-
orous, sustained CD4+ cell Th1 responses are associated with
viral clearance [16]. Moreover, broad cell-mediated immunity
within the first month after onset of symptoms represents an
efficient predictor of viral clearance [14]. The observation that
HCV RNA clearance was more likely to occur earlier among
subsets of patients with asymptomatic disease, rather than
among those with symptomatic acute hepatitis C, may reflect
a length-time bias; the true time of disease onset in patients
with asymptomatic cases might have been earlier than that
recorded, and in symptomatic patients, it may correspond al-
most exactly to what was recorded.
One of the main issues is the definition of the optimal time
to start treatment of acute hepatitis C. Is it better to initiate
immediate treatment, or is it better to delay treatment in order
to treat only those patients in whom HCV RNA remains de-
tectable after 12 weeks from disease onset, a period of time
after which a spontaneous clearance is unlikely to be achieved?
Progression to chronic illness should be prevented, but costly
and useless treatment of patients whose illness would sponta-
neously resolve should be avoided. Thus, the risks and benefits
of antiviral treatment should be carefully balanced. It has been
shown that delaying therapy until 8–12 weeks after the onset
of disease does not compromise the response to IFN treatment,
because starting therapy later yields the same rate of response
as earlier treatment [17]. However, it has been suggested that,
in contrast with patients who have symptomatic, acute HCV
infection, those with asymptomatic disease should receive im-
mediate antiviral treatment, because they have little chance of
achieving spontaneous viral clearance [10]. Our results show
that nearly all persons with acute, self-limiting hepatitis C, ei-
ther symptomatic or asymptomatic, experience spontaneous
HCV RNA clearance within 3 months after disease onset. On
the basis of these findings, it seems reasonable to suggest that
antiviral treatment be started 3 months after disease onset,
regardless of the presence of symptoms.
In conclusion, knowledge of the current sources of HCV
transmission may help to define more effective prevention strat-
egies and surveillance programs for high risk populations. This
would enable early detection of illness and eventual treatment
of newly acquired hepatitis C.
Acknowledgments
We acknowledge the other authors of this article: M. Fasano, A. Guas-
tadisegni, and S. Palattella (Clinic of Infectious Diseases, University of Bari,
Bari, Italy); M. P. Riccardi (Malattie Infettive, Grosseto, Italy); O. Bargiacchi
(Department of Infectious Diseases, University of Turin, Turin, Itlay); A.
Carlotto (Department of Infectious Diseases and Tropical Medicine, S.
Bortolo Hospital, Vincenza, Italy); and M. Mazzola (Division of Infectious
Diseases, Bisceglie Hospital, Bisceglie, Italy). We also are grateful to Ms.
Paulene Butts for her assistance in the preparation of the manuscript.
Potential conflicts of interest. All authors: no conflicts.
References
1. Mele A, Stroffolini T, Catapani R, et al. Incidence of transfusion as-
sociated B and non-A, non-B hepatitis in Italy. BMJ 1995; 311:846–7.
2. Kim WR. The burden of hepatitis C in the United States. Hepatology
2002; 36:S30–4.
3. Mele A, Tosti ME, Spada E, Kondili L, Marzolini F. SEIEVA (sistema
epidemiologico integrato delle epatiti virali acute). Rapporti ISTISAN.
Available at: http://www.epicentro.iss.it/problemi/epatite/epatiti.pdf.
Accessed 21 September 2006.
4. Tosti ME. Solinas S, Prati D, et al. An estimate of the current risk of
transmitting blood-borne infections through blood transfusion in Italy.
Br J Haematol 2002; 117:215–9.
5. Kondili LA, Chionne P, Costantino A, et al. Infection rate and spon-
taneous seroreversion of anti–hepatitis C virus during the natural
course of hepatitis C virus infection in the general population. Gut
2002; 50:693–6.
6. Mondelli MU, Cerino A, Cividini A. Acute hepatitis C: diagnosis and
management. J Hepatol 2005; 42:S108–14.
7. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hep-
atitis C with interferon alfa-2b. N Engl J Med 2001; 345:1452–7.
8. Santantonio T, Fasano M, Sinisi E, et al. Efficacy of a 24-week course
of peg-interferon a-2b monotherapy in patients with acute hepatitis
C after failure of spontaneous clearance. J Hepatol 2005; 42:329–33.
9. Mele A, Tosti ME, Marzolini A, et al. Prevention of hepatitis C in Italy:
lessons from surveillance of type-specific acute viral hepatitis. J Viral
Hepat 2000; 7:30–5.
10. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high
rate of both spontaneous and treatment induced viral clearance in
symptomatic patients. Gastroenterology 2003; 125:80–8.
11. Delwaide J, Bourgeois N, Gerard C, et al. Treatment of acute hepatitis
C with interferon a-2b: early initiation of treatment is the most effective
predictive factor of sustained viral response. Aliment Pharmacol Ther
2004; 20:15–22.
12. Wiegand J, Ja¨ckel E, Cornberg M, et al. Long-term follow-up after
successful interferon therapy of acute hepatitis C. Hepatology 2004;
40:98–107.
13. Santantonio T, Sinisi E, Guastadisegni A, et al. Natural course of acute
hepatitis C: a long-term prospective study. Dig Liver Dis 2003; 35:
104–13.
14. Spada E, Mele A, Berton A, et al. Multispecific T cell response and
negative HCV-RNA tests during acute HCV infection are early prog-
nostic factors of spontaneous clearance. Gut 2004; 53:1673–81.
15. Busch MP, Shafer KA. Acute-phase hepatitis C virus infection impli-
cations for research, diagnosis and treatment. Clin Infect Dis 2005; 40:
959–61.
16. Kamal SM, Rasenack JW, Bianchi L, et al. Acute hepatitis C without
and with schistosomiasis: correlation with hepatitis C–specific CD4+ T
cell and cytokine response. Gastroenterology 2001; 121:646–56.
17. Licata A, Di Bona D, Schepis F, et al. When and how to treat acute
hepatitis C? J Hepatol 2003; 39:1056–62.
